Cencora COR recently launched Cell and Gene Therapy (CGT) Enablement through its Accelerate Pharmacy Solutions business, offering support to health systems to evaluate, build and scale CGT programs. The new service is designed to improve operational readiness, financial confidence and program scalability while helping reduce barriers to care and expand patient access to advanced therapies.
Per management, cell and gene therapies have the potential to transform care for patients with serious and complex diseases, but delivering these therapies requires close coordination across strategy, finance, clinical operations, pharmacy and patient access. The company is building on its existing capabilities to provide health systems with tailored support, including market landscape and readiness assessments, governance design, implementation and optimization, to help them launch or expand their CGT programs.
Likely Trend of COR Stock Following the News
Shares of COR have inched up 0.3% since the announcement on Wednesday. Year to date, shares of the company have lost 0.2% against the industry’s 3.9% growth. The S&P 500 increased 12.5% in the same time frame.
The launch is likely to support Cencora’s long-term growth prospects by expanding its CGT capabilities and strengthening its relationships with health systems. As the number of approved therapies and clinical trials increases, health systems may require greater financial, operational and pharmacy support to integrate these complex treatments. Cencora’s new offering positions the company to capture the growing demand while complementing its existing CGT commercialization, specialty distribution and provider solutions.
COR currently has a market capitalization of $64.19 billion.
Image Source: Zacks Investment Research
More on the News
Cencora’s new CGT Enablement service comes as health systems face growing challenges in preparing for the increasing adoption of cell and gene therapies. More than 35 CGTs have been approved by the FDA so far, while more than 1,700 clinical trials are underway globally. However, only 4% of health system pharmacy leaders surveyed in a recent report said their organizations were fully prepared to integrate these therapies, highlighting significant gaps in infrastructure, resource allocation and operational alignment.
Cencora’s CGT Enablement team will support health systems across three areas. Financial confidence services will provide insights into the CGT market, therapy-specific financial considerations, reimbursement dynamics and site-of-care factors. Operational readiness support will include readiness assessments, gap analysis, strategic roadmaps, governance design and workflow planning. Scalable growth services will help establish repeatable operating models that support coordinated execution across pharmacy, finance, clinical operations, strategy and patient access teams.
The offering builds on Cencora’s broader CGT expertise across the product lifecycle, including commercialization support, specialty distribution and provider solutions. Cencora has completed 170 upstream CGT consulting projects, delivered more than 29,000 CGT shipments annually and supported 35 FDA-approved CGTs. By combining these capabilities with Accelerate Pharmacy Solutions’ pharmacy and supply chain expertise, the company aims to help health systems expand CGT programs across therapies, sites and indications.
Industry Prospects Favoring the Market
Going by the data provided by Fortune Business Insights, the global cell and gene therapy market is valued at $16.45 billion in 2026 and is expected to witness a CAGR of 31.1% through 2034.
Factors like the increasing prevalence of rare diseases and cancers, growing number of approved therapies, expanding clinical trial pipelines, rising demand for advanced treatments and increasing focus on operational readiness and patient access are supporting the market’s growth.
Other News
Cencora recently delivered mixed fiscal third-quarter 2026 results, with earnings beating estimates while revenues fell short. Performance was supported by specialty pharmaceutical volumes, GLP-1 demand and growth in international healthcare solutions. OneOncology boosted U.S. Healthcare Solutions, while Profarma and MWI Animal Health added to growth. The company raised its fiscal 2026 adjusted earnings outlook. However, lower-margin GLP-1 sales, higher OneOncology expenses and increased interest costs remain profitability headwinds.
In June, Cencora launched the next-generation Nucleus inventory management solution and initiated a multi-site pilot across more than 20 specialty physician practice locations. The enhanced platform is designed to help providers manage increasingly complex medication workflows with greater efficiency, visibility and control.
Cencora, Inc. Price
Cencora, Inc. price | Cencora, Inc. Quote
COR’s Zacks Rank & Key Picks
Currently, COR carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical GMED, Veracyte VCYT and West Pharmaceutical WST.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cencora, Inc. (COR): Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Veracyte, Inc. (VCYT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).